Grazia Marsico

Grazia Marsico

Auto-generated profile, based on publicly available information

Grazia Marsico

Synthetic and Systems Biology Lab for Biomedicine Istituto Italiano di Tecnologia‐IIT Largo Barsanti e Matteucci Naples 80125 Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DTDilip Thomas
Dilip Thomas
GMGrazia Marsico
Grazia Marsico
IIIsma Liza Mohd Isa
Isma Liza Mohd Isa
ATArun Thirumaran
Arun Thirumaran
XCXizhe Chen
Xizhe Chen
Abhay PanditAbhay Pandit
Abhay Pandit
Therapeutic factors secreted by mesenchymal stem cells (MSCs) promote angiogenesis in vivo. However, delivery of MSCs in the absence of a cytoprotective environment offers limited efficacy due to low cell retention, poor graft survival, and the nonmaintenance of a physiologically relevant dose of growth factors at the injury site. The delivery of stem cells on an extracellular matrix (ECM)-based platform alters cell behavior, including migration, proliferation, and paracrine activity, which are essential for angiogenesis. We demonstrate the biophysical and biochemical effects of preconditioning human MSCs (hMSCs) for 96 h on a three-dimensional (3D) ECM-based microgel platform. By altering the macromolecular concentration surrounding cells in the microgels, the proangiogenic phenotype of hMSCs can be tuned in a controlled manner through cell-driven changes in extracellular stiffness and “outside-in” integrin signaling. The softest microgels were tested at a low cell dose (5 × 104 cells) in a preclinical hindlimb ischemia model showing accelerated formation of new blood vessels with a reduced inflammatory response impeding progression of tissue damage. Molecular analysis revealed that several key mediators of angiogenesis were up-regulated in the low-cell-dose microgel group, providing a mechanistic insight of pathways modulated in vivo. Our research adds to current knowledge in cell-encapsulation strategies by highlighting the importance of preconditioning or priming the capacity of biomaterials through cell–material interactions. Obtaining therapeutic efficacy at a low cell dose in the microgel platform is a promising clinical route that would aid faster tissue repair and reperfusion in “no-option” patients suffering from peripheral arterial diseases, such as critical limb ischemia (CLI). Significance An optimal 3D cell-delivery platform is key for cytoprotection and prolonged cell function in vivo for sustained delivery of therapeutic factors as “cell factories.” However, little is known about stem-cell phenotype and behavior resulting from in vitro preconditioning in engineered extracellular matrices. We demonstrate a close relationship between macromolecular concentration and mesenchymal stem cell behavior that drives morphological changes, modulation of integrin expression, and matrix rigidity after 96 h of in vitro preconditioning. Changes induced by the optimal microenvironment influence a proangiogenic phenotype of mesenchymal stem cells in a concentration-dependent manner and play a key role in promoting angiogenesis in vivo at a 20 times lower cell dose than the preclinical standard, tested in a severe, double-ligation model of CLI.

1 January 2020 in Materials Today Bio
Verified
Journal Article
Open access
RSRenza Spelat
Renza Spelat
FFFederico Ferro
Federico Ferro
PCPaolo Contessotto
Paolo Contessotto
NWNicholas J. Warren
Nicholas J. Warren
GMGrazia Marsico
Grazia Marsico
Abhay PanditAbhay Pandit
Abhay Pandit
Multiple myeloma (MM) is a malignancy of terminally-differentiated plasma cells that develops mainly inside the bone marrow (BM) microenvironment. It is well known that autocrine and paracrine signals are responsible for the progression of this disease but the precise mechanism and contributions from single cell remain largely unknown. Mesenchymal stem cells (MSC) are an important cellular component of the BM: they support MM growth by increasing its survival and chemo-resistance, but little is known about the paracrine signaling pathways. Three-dimensional (3D) models of MM-MSC paracrine interactions are much more biologically-relevant than simple 2D models and are considered essential for detailed studies of MM pathogenesis. Herein we present a novel 3D co-culture model designed to mimic the paracrine interaction between MSC and MM cells. MSC were embedded within a previously characterized thermoresponsive block copolymer worm gel that can induce stasis in human pluripotent stem cells (hPSC) and then co-cultured with MM cells. Transcriptional phenotyping of co-cultured cells indicated the dysregulation of genes that code for known disease-relevant factors, and also revealed IL-6 and IL-10 as upstream regulators. Importantly, we have identified a synergistic paracrine signaling pathway between IL-6 and IL-10 that plays a critical role in sustaining MM cell proliferation. Our findings indicate that this 3D co-culture system is a useful model to investigate the paracrine interaction between MM cells and the BM microenvironment in vitro. This approach has revealed a new mechanism that promotes the proliferation of MM cells and suggested a new therapeutic target.

1 September 2025 in Small
Verified
Journal Article
Open access
GMGrazia Marsico
Grazia Marsico
SGSudarshan Gc
Sudarshan Gc
VSVelia Siciliano
Velia Siciliano
Chimeric antigen receptor (CAR)‐T cell immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering new hope across various malignancies. However, its success against solid tumors remains limited due to critical challenges, including off‐tumor, on‐target toxicity, immune resistance, poor T cell infiltration into the tumor microenvironment (TME), and T cell exhaustion. In response, interdisciplinary innovations in synthetic biology and biomaterials are redefining how can be engineer smarter, more responsive CAR‐T cells. Recent advances have introduced biomaterials not only as precision delivery vehicles but also as artificial antigen‐presenting cells (APCs), high‐throughput screening platforms, and tools to replicate the complex biomechanical landscape of the TME. This review highlights these cutting‐edge strategies, emphasizing how biomaterials and synthetic circuits can aid studies and strategies to enhance CAR‐T cell efficacy in solid tumors while minimizing adverse effects. Future directions at the intersection of tumor‐inspired biomaterials and T cell engineering, envisioning a new generation of CAR‐T therapies tailored to overcome the formidable barriers of the TME are also explored.